Hansoh Pharmaceutical (03692.HK) Rises Over 3% as Amilect®’s NDA for Lung Cancer Adjuvant Therapy Accepted in China

According to the Zhicheng Finance APP, Hansoh Pharma (03692) rose over 3%. As of press time, it increased by 3.24%, trading at HK$17.80, with a turnover of HK$23.77 million.

On the news front, recently, Hansoh Pharma announced that the marketing authorization application for Ameile (Amoy Medical's innovative Class 1 drug) developed by its subsidiary, Jiangsu Hengsen Pharmaceutical Group Co., Ltd., was accepted by the National Medical Products Administration of the People’s Republic of China. Ameile is intended for adjuvant treatment in adult patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutation-positive non-small cell lung cancer (NSCLC) following tumor resection. This application marks the third indication for Ameile.